Wall Street Journal: Weight-Loss Drug Wegovy Also Works Against Heart Failure

There is new evidence that a popular weight-loss drug can deliver health benefits beyond shedding pounds. Novo Nordisk’s anti-obesity drug Wegovy eased the symptoms of a common form of heart failure in patients who also have obesity, researchers reported Friday.

The patients who took the once-weekly injection for a year reported improvements in fatigue and shortness of breath, and found they could walk longer distances, all while losing an average of 13% of their body weight.

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the study and presented the findings of STEP-HFpEF trial during the opening late breaking clinical trial session at the European Society of Cardiology Congress (ESC Congress) in Amsterdam, Netherlands. 

Read the full article on Wall Street Journal: Weight-Loss Drug Wegovy Also Works Against Heart Failure

Related Content

Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Aug. 26, 2023

Good Morning America: New Study Highlights Benefits to Weight Loss Drugs
Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.